What is CHO Cell Line and Why Is It Common in Biologics?

Chinese Hamster Ovary (CHO) cell lines are a pivotal component in the field of biotechnology, especially when it comes to the production of biologics. These cells have become the workhorse for the biopharmaceutical industry, largely due to their unique characteristics that make them suitable for producing complex proteins and other therapeutic agents.

CHO cells are derived from the ovary of the Chinese hamster, a species that may seem an unlikely source for such an important tool in modern medicine. However, they offer several advantages that make them ideal for use in biologics manufacturing. One of the primary reasons for their popularity is their ability to grow in suspension culture, which allows for the scalable production of biologics in large bioreactors. This is a crucial factor when it comes to meeting the high demand for therapeutic proteins worldwide.

Another significant advantage of CHO cells is their adaptability. They can be genetically manipulated with relative ease, allowing scientists to introduce specific genes that code for the desired therapeutic proteins. This adaptability is important because it enables the production of a wide range of biologics, including monoclonal antibodies, hormones, and enzymes, among others. Moreover, CHO cells are known for their robustness and stability, often maintaining high levels of productivity over extended periods, which is essential for commercial production.

CHO cells also have a proven track record of safely producing proteins that are compatible with human use. They have the ability to perform post-translational modifications, a critical process for ensuring that the proteins produced are similar to those naturally found in the human body. This is important because proper folding and modification of proteins are required for their effectiveness and safety as therapeutics.

The regulatory familiarity with CHO cell lines further cements their role in the production of biologics. Over the years, they have been used to produce numerous FDA-approved biologics, providing a wealth of data and experience that facilitates the approval process for new products. Regulatory agencies around the world are well-acquainted with the safety and efficacy profiles of proteins produced using CHO cell lines, which often streamlines the approval process for new therapies.

In addition to these practical and regulatory advantages, CHO cells also present fewer ethical concerns compared to other cell lines. They are not derived from human or primate sources, thereby avoiding the complex ethical issues associated with some other cell lines used in biopharmaceutical production.

The widespread use of CHO cells in the production of biologics is a testament to their versatility and effectiveness. As the biopharmaceutical industry continues to grow, the demand for biologics is expected to increase, further solidifying the role of CHO cell lines in the production of these critical therapies. Researchers continue to innovate and improve CHO cell line technologies, such as optimizing culture conditions and enhancing genetic engineering techniques, ensuring that this cell line remains at the forefront of biologics manufacturing.

In conclusion, the prominence of CHO cell lines in the production of biologics can be attributed to their adaptability, scalability, safety, and regulatory acceptance. These cells have revolutionized the field of biotechnology, enabling the large-scale production of complex therapeutics that have the potential to treat a wide array of diseases and improve the quality of life for countless individuals around the globe.

For an experience with the large-scale biopharmaceutical model Hiro-LS, please click here for a quick and free trial of its features！